---
title: "Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $19.2, Implies 10% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294081424.md"
description: "Takeda Pharmaceutical's 12-month average price target was raised to $19.20 by 13 analysts, up from $19.01, implying a 10% upside based on the July 27 closing price. The consensus rating remains 'Buy' among 15 covering analysts, comprising 9 Buys and 6 Holds."
datetime: "2026-07-28T14:20:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294081424.md)
  - [en](https://longbridge.com/en/news/294081424.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294081424.md)
generator: "portal-rs"
---

# Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $19.2, Implies 10% Upside

-   According to estimates from 13 analysts, Takeda Pharmaceutical Company Limited stock's average price target has risen from $19.01 to $19.2, with forecasts ranging from $17.27 to $21.28 per share
-   Based on the Jul. 27 closing price, the updated target implies approximately 10% potential upside
-   Consensus rating remains at “Buy” across 15 covering analysts, with 9 Buys, 6 Holds and 0 Sells

Explore more price target data and ratings for Takeda Pharmaceutical Company Limited on the , and track all previous and future analyst recommendations for Takeda Pharmaceutical Company Limited in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO](https://longbridge.com/en/news/297377145.md)
- [Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1](https://longbridge.com/en/news/296890461.md)
- [Takeda adds boxed warning on ADZYNMA over risk of neutralizing antibodies to ADAMTS13](https://longbridge.com/en/news/296794493.md)
- [Takeda says Japan approves ORZEYFUL to treat narcolepsy type 1 in adults](https://longbridge.com/en/news/296745287.md)
- [ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 | TAK Stock News](https://longbridge.com/en/news/296745786.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**